CXCR4 and prostate carcinoma: Whilst Shiozawa et al. [76] demonstrated that CXCR4 inhibition decreased bone marrow prostate cancer cells by inducing the mobilization of the tumor cells back into the circulation, Wang et al. [134] showed that the same treatment regime did not affect the number of prostate DTCs that homed to the bone, but instead altered the distribution.